Safety of panitumumab, a fully human monoclonal antibody against the epidermal growth factor receptor (EGFr), in patients (pts) with metastatic colorectal cancer (mCRC) across clinical trials

被引：0
|
作者：
Peeters, M.
Van Cutsem, E.
Berlin, J.
Hecht, J. R.
Ruiz, R.
Navale, L.
Amado, R.
Meropol, N. J.
机构：
[1] Ghent Univ Hosp, Ghent, Belgium
[2] Univ Hosp Gasthuisberg, Leuven, Belgium
[3] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[4] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA
[5] Amgen Inc, Thousand Oaks, CA 91320 USA
[6] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4138
引用
收藏
页数：2
相关论文
共 50 条
  • [41] The role of anti-epidermal growth factor receptor monoclonal antibody monotherapy in the treatment of metastatic colorectal cancer
    Bouche, Olivier
    Beretta, Giordano Domenico
    Garcia Alfonso, Pilar
    Geissler, Michael
    CANCER TREATMENT REVIEWS, 2010, 36 : S1 - S10
  • [42] Cetuximab with irinotecan in first-line treatment of epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer (mCRC): Preliminary safety results (CRYSTAL).
    Lang, I.
    Zaluski, J.
    Changchien, C. R.
    Makhson, A.
    Pinter, T.
    D'Haens, G.
    Lim, R.
    Nippgen, J.
    Van Cutsem, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 159S - 159S
  • [43] Safety and pharmacokinetics (PK) of AMG 706 with panitumumab plus FOLFIRI or FOLFOX for the treatment of patients (pts) with metastatic colorectal cancer (mCRC)
    Schwartzberg, L. S.
    Hurwitz, H.
    Stephenson, J., Jr.
    Kotasek, D.
    Goldstein, D.
    Tebbutt, N.
    McGreivy, J.
    Sun, Y.
    Yang, L.
    Burris, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [44] Results of monoclonal antibodies against EGFR-receptors application in patients with metastatic colorectal cancer (mCRC).
    Vladimirova, Liubov Yu
    Kit, Oleg Ivanovich
    Nikipelova, Elena A.
    Abramova, Natalya A.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [45] Clinical Pharmacokinetics and Pharmacodynamics of the Epidermal Growth Factor Receptor Inhibitor Panitumumab in the Treatment of Colorectal Cancer
    Sander Ketzer
    Kirsten Schimmel
    Miriam Koopman
    Henk-Jan Guchelaar
    Clinical Pharmacokinetics, 2018, 57 : 455 - 473
  • [46] Clinical Pharmacokinetics and Pharmacodynamics of the Epidermal Growth Factor Receptor Inhibitor Panitumumab in the Treatment of Colorectal Cancer
    Ketzer, Sander
    Schimmel, Kirsten
    Koopman, Miriam
    Guchelaar, Henk-Jan
    CLINICAL PHARMACOKINETICS, 2018, 57 (04) : 455 - 473
  • [47] Clinical use of monoclonal antibodies to the epidermal growth factor receptor in colorectal cancer
    Burtness, Barbara
    ONCOLOGY-NEW YORK, 2007, 21 (08): : 964 - 970
  • [48] Association of somatic KRAS gene mutations and clinical outcome in patients (pts) with metastatic colorectal cancer (mCRC) receiving panitumumab monotherapy
    Freeman, D.
    Juan, T.
    Meropol, N. J.
    Hecht, J. R.
    Berlin, J.
    Van Cutsem, E.
    Reiner, M.
    Radinsky, R.
    Amado, R. G.
    Peeters, M.
    EJC SUPPLEMENTS, 2007, 5 (04): : 239 - 239
  • [49] Patient-reported outcome (PRO)-assessed clinical benefit with panitumumab (Pmab) in metastatic colorectal cancer (mCRC) patients (pts)
    Hendlisz, A.
    Van Cutsem, E.
    Peeters, M.
    Humblet, Y.
    Neyns, B.
    Sobrero, A.
    Devercelli, G.
    Wolf, M.
    Amado, R. G.
    Siena, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [50] Drug insight: panitumumab, a human EGFR-targeted monoclonal antibody with promising clinical activity in colorectal cancer
    Mano, Max
    Humblet, Yves
    NATURE CLINICAL PRACTICE ONCOLOGY, 2008, 5 (07): : 415 - 425
12345